Baidu
map

Lancet respir med:依法卡托可用于1-2岁囊性纤维化患儿,疗效好、安全性高

2018-06-08 MedSci MedSci原创

注释:囊性纤维化是一种遗传性外分泌腺疾病,主要影响胃肠道和呼吸系统,通常具有慢性梗阻性肺部病变、胰腺外分泌功能不良和汗液电解质异常升高的特征。Ivacaftor(依法卡托)对于2岁及以上的携带特异性CFTR突变的囊性纤维化患儿一般是安全有效的。依法卡托是否可用于2岁以下的患儿尚无明确数据,现研究人员对依法卡托用于1-2岁的携带特异性CFTR突变的囊性纤维化患儿的疗效和安全性进行评估。研究人员进行一

注释:囊性纤维化是一种遗传性外分泌腺疾病,主要影响胃肠道和呼吸系统,通常具有慢性梗阻性肺部病变、胰腺外分泌功能不良和汗液电解质异常升高的特征。

Ivacaftor(依法卡托)对于2岁及以上的携带特异性CFTR突变的囊性纤维化患儿一般是安全有效的。依法卡托是否可用于2岁以下的患儿尚无明确数据,现研究人员对依法卡托用于1-2岁的携带特异性CFTR突变的囊性纤维化患儿的疗效和安全性进行评估。

研究人员进行一多中心的、单臂、两队列的3期临床试验(ARRIVAL),招募1-2岁(不满2岁)的已确诊的携带特异性CFTR突变的囊性纤维化患儿。予以依法卡托 50mg(体重在7-14kg)或75mg(14-25kg)口服 ,12小时一次。A队列患儿(招募自7个地方)治疗3天半;B队列患儿(招募自13个地方)持续治疗24周。主要结点:药物代谢动力学(A队列)和安全性(A和B队列)。B队列的次要结点是至少接受一次依法卡托治疗的患儿的药代动力学以及汗液氯化物浓度的绝对变化值。

2016年8月25日-2017年11月1日,A队列研究招募了7位患儿,其中5位的治疗剂量为50mg、2位为75mg,均完成治疗;B队列研究招募了19位患儿,其中一位来自A队列,所有患儿的治疗剂量均为50mg,18位患儿完成治疗(1位因抽血困难而退出)。

药代学提示药物暴露量与2-6岁和成人相似。无需中断治疗的副反应发生。A队列3位(43%)患儿发生需紧急治疗的轻度副反应,经分析认为与依法卡托无关。24周时,B队列19位患儿中有18位(95%)出现需紧急治疗的副反应,大多为轻中度,最常见是咳嗽(14位[74%])。B队列2位患儿发生4例严重副反应:1位发生便秘(可能与依法卡托相关)、末端肠梗阻和疱疹样湿疹,另1位患儿发生持续性咳嗽,均需要住院治疗。18位患儿中有5位(18%)出现天冬氨酸或丙氨酸转氨酶升高超过正常上限的3倍(在两个同时合并感染的患儿中升高达8倍)。24周时,汗液氯化物浓度绝对变化值的平均值(与起始相比)为-73.5(SD 17.5)mmol/L。生长参数正常。与起始相比,24周时,大便弹性蛋白酶-1增多、免疫反应性胰蛋白酶原减少。起始时血清脂肪酶和淀粉酶均升高,开始治疗后均迅速降低。

依法卡托用于1-2岁幼儿长达24周,安全、耐受性良好,并可迅速降低汗液氯化物浓度并维持。胰腺功能的生物标志物升高提示早期应用依法卡托可保留胰腺的外分泌功能。目前正在12月内的新生儿中继续该项研究。

原始出处:

Margaret Rosenfeld,et al.Ivacaftor treatment of cystic fibrosis in children aged 12 to <24 months and with a CFTR gating mutation (ARRIVAL): a phase 3 single-arm study.The Lancet Respiratory Medicine. June 06,2018.https://doi.org/10.1016/S2213-2600(18)30202-9

本文系梅斯医学(MedSci)原创编译,转载需授权!

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1675866, encodeId=951816e5866b4, content=<a href='/topic/show?id=7395403e580' target=_blank style='color:#2F92EE;'>#囊性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=40375, encryptionId=7395403e580, topicName=囊性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=926927300775, createdName=wolongzxh, createdTime=Sun Sep 23 21:14:00 CST 2018, time=2018-09-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1829669, encodeId=f6ee18296690d, content=<a href='/topic/show?id=1b6210686b2' target=_blank style='color:#2F92EE;'>#Lancet#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10686, encryptionId=1b6210686b2, topicName=Lancet)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3f0227, createdName=howi, createdTime=Wed Dec 26 13:14:00 CST 2018, time=2018-12-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1608867, encodeId=2827160886e2e, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Sun Jun 10 00:14:00 CST 2018, time=2018-06-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1031801, encodeId=bfc3103180159, content=谢谢梅斯提供这么好的信息,学到很多, beContent=null, objectType=article, channel=null, level=null, likeNumber=85, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=内科新手, createdTime=Fri Jun 08 12:14:00 CST 2018, time=2018-06-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=322468, encodeId=f2c432246805, content=学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmhead/Q3auHgzwzM6P57Bs8gOPaY1cQP9lIia0lmZOEXraGaoicqNToIslXDKw/0, createdBy=7a041951742, createdName=衣带渐宽, createdTime=Fri Jun 08 10:36:40 CST 2018, time=2018-06-08, status=1, ipAttribution=)]
    2018-09-23 wolongzxh
  2. [GetPortalCommentsPageByObjectIdResponse(id=1675866, encodeId=951816e5866b4, content=<a href='/topic/show?id=7395403e580' target=_blank style='color:#2F92EE;'>#囊性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=40375, encryptionId=7395403e580, topicName=囊性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=926927300775, createdName=wolongzxh, createdTime=Sun Sep 23 21:14:00 CST 2018, time=2018-09-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1829669, encodeId=f6ee18296690d, content=<a href='/topic/show?id=1b6210686b2' target=_blank style='color:#2F92EE;'>#Lancet#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10686, encryptionId=1b6210686b2, topicName=Lancet)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3f0227, createdName=howi, createdTime=Wed Dec 26 13:14:00 CST 2018, time=2018-12-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1608867, encodeId=2827160886e2e, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Sun Jun 10 00:14:00 CST 2018, time=2018-06-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1031801, encodeId=bfc3103180159, content=谢谢梅斯提供这么好的信息,学到很多, beContent=null, objectType=article, channel=null, level=null, likeNumber=85, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=内科新手, createdTime=Fri Jun 08 12:14:00 CST 2018, time=2018-06-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=322468, encodeId=f2c432246805, content=学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmhead/Q3auHgzwzM6P57Bs8gOPaY1cQP9lIia0lmZOEXraGaoicqNToIslXDKw/0, createdBy=7a041951742, createdName=衣带渐宽, createdTime=Fri Jun 08 10:36:40 CST 2018, time=2018-06-08, status=1, ipAttribution=)]
    2018-12-26 howi
  3. [GetPortalCommentsPageByObjectIdResponse(id=1675866, encodeId=951816e5866b4, content=<a href='/topic/show?id=7395403e580' target=_blank style='color:#2F92EE;'>#囊性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=40375, encryptionId=7395403e580, topicName=囊性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=926927300775, createdName=wolongzxh, createdTime=Sun Sep 23 21:14:00 CST 2018, time=2018-09-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1829669, encodeId=f6ee18296690d, content=<a href='/topic/show?id=1b6210686b2' target=_blank style='color:#2F92EE;'>#Lancet#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10686, encryptionId=1b6210686b2, topicName=Lancet)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3f0227, createdName=howi, createdTime=Wed Dec 26 13:14:00 CST 2018, time=2018-12-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1608867, encodeId=2827160886e2e, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Sun Jun 10 00:14:00 CST 2018, time=2018-06-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1031801, encodeId=bfc3103180159, content=谢谢梅斯提供这么好的信息,学到很多, beContent=null, objectType=article, channel=null, level=null, likeNumber=85, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=内科新手, createdTime=Fri Jun 08 12:14:00 CST 2018, time=2018-06-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=322468, encodeId=f2c432246805, content=学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmhead/Q3auHgzwzM6P57Bs8gOPaY1cQP9lIia0lmZOEXraGaoicqNToIslXDKw/0, createdBy=7a041951742, createdName=衣带渐宽, createdTime=Fri Jun 08 10:36:40 CST 2018, time=2018-06-08, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1675866, encodeId=951816e5866b4, content=<a href='/topic/show?id=7395403e580' target=_blank style='color:#2F92EE;'>#囊性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=40375, encryptionId=7395403e580, topicName=囊性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=926927300775, createdName=wolongzxh, createdTime=Sun Sep 23 21:14:00 CST 2018, time=2018-09-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1829669, encodeId=f6ee18296690d, content=<a href='/topic/show?id=1b6210686b2' target=_blank style='color:#2F92EE;'>#Lancet#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10686, encryptionId=1b6210686b2, topicName=Lancet)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3f0227, createdName=howi, createdTime=Wed Dec 26 13:14:00 CST 2018, time=2018-12-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1608867, encodeId=2827160886e2e, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Sun Jun 10 00:14:00 CST 2018, time=2018-06-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1031801, encodeId=bfc3103180159, content=谢谢梅斯提供这么好的信息,学到很多, beContent=null, objectType=article, channel=null, level=null, likeNumber=85, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=内科新手, createdTime=Fri Jun 08 12:14:00 CST 2018, time=2018-06-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=322468, encodeId=f2c432246805, content=学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmhead/Q3auHgzwzM6P57Bs8gOPaY1cQP9lIia0lmZOEXraGaoicqNToIslXDKw/0, createdBy=7a041951742, createdName=衣带渐宽, createdTime=Fri Jun 08 10:36:40 CST 2018, time=2018-06-08, status=1, ipAttribution=)]
    2018-06-08 内科新手

    谢谢梅斯提供这么好的信息,学到很多

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=1675866, encodeId=951816e5866b4, content=<a href='/topic/show?id=7395403e580' target=_blank style='color:#2F92EE;'>#囊性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=40375, encryptionId=7395403e580, topicName=囊性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=926927300775, createdName=wolongzxh, createdTime=Sun Sep 23 21:14:00 CST 2018, time=2018-09-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1829669, encodeId=f6ee18296690d, content=<a href='/topic/show?id=1b6210686b2' target=_blank style='color:#2F92EE;'>#Lancet#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10686, encryptionId=1b6210686b2, topicName=Lancet)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3f0227, createdName=howi, createdTime=Wed Dec 26 13:14:00 CST 2018, time=2018-12-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1608867, encodeId=2827160886e2e, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Sun Jun 10 00:14:00 CST 2018, time=2018-06-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1031801, encodeId=bfc3103180159, content=谢谢梅斯提供这么好的信息,学到很多, beContent=null, objectType=article, channel=null, level=null, likeNumber=85, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=内科新手, createdTime=Fri Jun 08 12:14:00 CST 2018, time=2018-06-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=322468, encodeId=f2c432246805, content=学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmhead/Q3auHgzwzM6P57Bs8gOPaY1cQP9lIia0lmZOEXraGaoicqNToIslXDKw/0, createdBy=7a041951742, createdName=衣带渐宽, createdTime=Fri Jun 08 10:36:40 CST 2018, time=2018-06-08, status=1, ipAttribution=)]
    2018-06-08 衣带渐宽

    学习

    0

相关资讯

Diabetes Care:胰岛白细胞介素-1β免疫反应性是囊性纤维化的早期特征!

这些发现揭示了CF患者潜在胰岛病理新的分子途径和治疗靶点,可能在开发CFRD新治疗方法上具有重要的价值。

儿童囊性纤维化影像学表现2例报告与临床分析

囊性纤维化(Cysticfibrosis,CF)是欧美白种人最常见的致死性常染色体隐性遗传病,而亚洲人和非洲人少见。国内只有少数报道,影像学表现报道就更罕见。本文报道2例临床确诊CF病例的影像学表现,并结合文献对CF临床及影像诊断提出一点经验,旨在提高对本病的诊断水平。

2017 共识建议:囊性纤维化结直肠癌筛查

成人囊性纤维化患者结直肠癌风险是普通人群的5-10倍。本文是由18位专家组成的囊性纤维化结直肠癌筛查工作组共同商讨形成的,主要针对囊性纤维化成人患者结直肠癌的筛查提供共识建议。

Lancet Diabetes Endocrinol:囊性纤维化新诊断糖尿病患者,瑞格列奈vs胰岛素

2018年2月,发表在《Lancet Diabetes Endocrinol》的一项由德国、法国和意大利科学家进行的多中心、开放标签、随机试验,考察了瑞格列奈vs胰岛素治疗囊性纤维化新诊断糖尿病患者的有效性和安全性。

NEJM:新生儿囊性纤维化胎粪性肠梗阻-病例报道

胎粪性肠梗阻,可能是囊性纤维化的早期表现,也可发生于极低出生体重早产儿。肠梗阻是浓缩的胎粪在回肠腔内积累的结果。对胎粪延迟排出的鉴别诊断包括先天性巨结肠和胎粪栓综合征。

囊性纤维化:抗生素相关性肾损伤的检测

遗传性疾病囊性纤维化(CF)的特征是继发性细菌性肺部感染,常由特定的耐药细菌铜绿假单胞菌所致。而氨基糖苷类抗生素对这种细菌具有良好的作用,常被用于治疗这些感染。但是,氨基糖苷类抗生素可能会损害肾脏。尽管有降低风险的策略,但氨基糖苷类抗生素的暴露与囊性纤维化患儿的急性肾损伤(AKI)密切相关。

Baidu
map
Baidu
map
Baidu
map